on ONCODESIGN PRECISION MEDICINE S.A. (isin : FR001400CM63)
Oncodesign Precision Medicine's Half-Year Financial Results and Clinical Updates
Oncodesign Precision Medicine (OPM) released its financial results for the first half of 2026, ending June 30. OPM reported revenue of €0.11 million, a slight decrease from €0.14 million in 2025. Funded by the Michael J. Fox Foundation, OPM-201 is progressing in Parkinson's research. OPM has maintained cost-cutting strategies from previous years, leading to a significant reduction in operating expenses.
Operating results improved by 32%, excluding the 2025 non-recurring effects, showing a loss of -€2.2 million. The net loss was €2.0 million, representing a 35% improvement from the previous year's half. These figures indicate effective management despite challenging conditions.
R&D expenditure dropped by 49%, emphasizing strategic program investments. OPM's cash position was €2.86 million, supported by the Michael J. Fox Foundation's grant. OPM continues to explore partnerships for its OPM-101 and OPM-201 assets.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ONCODESIGN PRECISION MEDICINE S.A. news